Cytotoxicity of Mebendazole Against Established Cell Lines from the Human, Rat, and Mouse Liver

Overview

Journal Arch Toxicol

Specialty Toxicology

Date 1992 Jan 1

PMID 1497489

Authors

F Higa

K Kitsukawa

M Gaja

M Tateyama

K Shikiya

Y Shigeno

F Kinjo

A Saito

Affiliations

Soon will be listed here.

Abstract

The direct cytotoxicity of mebendazole (MBZ) was investigated by using cell lines derived from human, mouse and rat liver. It was demonstrated that Chang liver cells (derived from human liver) were more sensitive to the cytotoxic effects of MBZ than the other two cell lines. Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture). Inhibition of the proliferation of Chang liver cells by MBZ was detected at a concentration of 0.008 mg/l, a lower concentration than that having a cytotoxic effect. The other two cell lines were less sensitive to the inhibitory effect of MBZ. Proliferation of human mononuclear cells following stimulation by phytohemagglutinin (PHA) was inhibited by MBZ, and this inhibition was more extensive than that of cells stimulated with whole formalin-treated Pseudomonas aeruginosa. It is suggested that dividing cells may be more sensitive to MBZ cytotoxicity. This anti-proliferative effect may be related to its clinically known side effects, such as hepatotoxicity and bone marrow suppression.

References

Woodtli W, BIRCHER J, Witassek F, Eckert J, Wuthrich B, Ammann R . Effect of plasma mebendazole concentrations in the treatment of human echinococcosis. Am J Trop Med Hyg. 1985; 34(4):754-60. DOI: 10.4269/ajtmh.1985.34.754. View

Braithwaite P, Roberts M, Allan R, Watson T . Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. Eur J Clin Pharmacol. 1982; 22(2):161-9. DOI: 10.1007/BF00542462. View

Witassek F, BIRCHER J . Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level. Eur J Clin Pharmacol. 1983; 25(1):85-90. DOI: 10.1007/BF00544021. View

Shikiya K, Kuniyoshi T, Higashionna A, Arakkaki T, Oyakawa T, Kadena K . [Treatment of strongyloidiasis with mebendazole and its combination with thiabendazole]. Kansenshogaku Zasshi. 1990; 64(11):1408-15. DOI: 10.11150/kansenshogakuzasshi1970.64.1408. View

Seitz R, Schwerk W, Arnold R . [Hepatocellular drug reaction caused by mebendazole therapy in cystic echinococcosis]. Z Gastroenterol. 1983; 21(7):324-9. View

Musgrave I, Hawes R, Jameson J, Sloane R, Quayle P . Evaluation of a new antihelminthic for trichuriasis, hookworm, and stronglyloidiasis. Med J Aust. 1979; 1(9):403-5. View

Murray-Lyon I, Reynolds K . Complication of mebendazole treatment for hydatid disease. Br Med J. 1979; 2(6198):1111-2. PMC: 1596999. DOI: 10.1136/bmj.2.6198.1111-a. View

VAN DEN BOSSCHE H, Rochette F, Horig C . Mebendazole and related anthelmintics. Adv Pharmacol Chemother. 1982; 19:67-128. DOI: 10.1016/s1054-3589(08)60021-6. View

Davis A, Pawlowski Z, Dixon H . Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis. Bull World Health Organ. 1986; 64(3):383-8. PMC: 2490884. View

10.

Mravak S, SCHOPP W, Bienzle U . Treatment of strongyloidiasis with mebendazole. Acta Trop. 1983; 40(1):93-4. View

11.

Luder P, Siffert B, Witassek F, Meister F, BIRCHER J . Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions. Eur J Clin Pharmacol. 1986; 31(4):443-8. DOI: 10.1007/BF00613522. View

12.

van Hoegaerden M, Ivanoff B, Flocard F, Salle A, Chabaud B . The use of mebendazole in the treatment of filariases due to Loa loa and Mansonella perstans. Ann Trop Med Parasitol. 1987; 81(3):275-82. DOI: 10.1080/00034983.1987.11812120. View

13.

Grove D . Strongyloides ratti and S. stercoralis: the effects of thiabendazole, mebendazole, and cambendazole in infected mice. Am J Trop Med Hyg. 1982; 31(3 Pt 1):469-76. DOI: 10.4269/ajtmh.1982.31.469. View

14.

Horstmann R, Kern P, VOLKMER K, Dietrich M . Observations on mebendazole vs. thiabendazole in the treatment of human trichinellosis. Tropenmed Parasitol. 1982; 33(3):191-4. View

15.

Bekhti A, PIROTTE J . Hepatotoxicity of mebendazole. Relationship with serum concentrations of the drug. Gastroenterol Clin Biol. 1987; 11(10):701-3. View

16.

Munst G, Karlaganis G, BIRCHER J . Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results. Eur J Clin Pharmacol. 1980; 17(5):375-8. DOI: 10.1007/BF00558451. View

17.

Michiels M, Hendriks R, Heykants J, VAN DEN BOSSCHE H . The pharmacokinetics of mebendazole and flubendazole in animals and man. Arch Int Pharmacodyn Ther. 1982; 256(2):180-91. View

18.

Harris A . Pyrexia and mebendazole. Br Med J. 1979; 2(6201):1365. PMC: 1597314. DOI: 10.1136/bmj.2.6201.1365. View

19.

Marsboom R . Toxicologic studies on mebendazole. Toxicol Appl Pharmacol. 1973; 24(3):371-7. DOI: 10.1016/0041-008x(73)90043-4. View